search
Back to results

Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Aliskiren
Aliskiren
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hypertension focused on measuring Aliskiren,, hypertension,, renin-angiotensin-aldosterone system,, pharmacokinetics,, pharmacodynamics

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female outpatients, 18 to 65 years of age with mild to moderate hypertension
  • Patients who are eligible and able to participate in the study

Exclusion criteria:

  • Severe hypertension
  • Secondary form of hypertension.
  • Type 1 or type 2 diabetes mellitus
  • Serum potassium out side laboratory reference range
  • Any history of hypertensive encephalopathy or cerebrovascular accident

Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigator Site
  • Novartis Investigative Site
  • Novartis Investigator Site
  • Novartis Investigator Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Fed Group

Fasted group

Arm Description

Outcomes

Primary Outcome Measures

Compare PK (AUC & Cmax) and PD, i.e. PRA (Plasma Renin Activity, AUE) of aliskiren when given with and without light meal.

Secondary Outcome Measures

Compare the effect of Plasma Renin Concentration (PRC) and angiotensin II of aliskiren when given with and without light meal
Assess safety and tolerability of aliskiren when given with and without light meal
Evaluate the effect on mean sitting systolic and diastolic blood pressure of aliskiren when given with or without a light meal

Full Information

First Posted
July 3, 2009
Last Updated
December 17, 2020
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00933920
Brief Title
Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension
Official Title
A Randomized, Single-blind, Parallel Group, Multiple Oral Dose Study to Evaluate the Effect of a Light Meal on the Pharmacokinetics and Pharmacodynamics of Aliskiren Using Market 300 mg Tablet Formulation in Subjects With Mild to Moderate Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
February 2010
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren in patients with mild to moderate hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Aliskiren,, hypertension,, renin-angiotensin-aldosterone system,, pharmacokinetics,, pharmacodynamics

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
124 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fed Group
Arm Type
Active Comparator
Arm Title
Fasted group
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Aliskiren
Intervention Type
Drug
Intervention Name(s)
Aliskiren
Primary Outcome Measure Information:
Title
Compare PK (AUC & Cmax) and PD, i.e. PRA (Plasma Renin Activity, AUE) of aliskiren when given with and without light meal.
Time Frame
28 Days
Secondary Outcome Measure Information:
Title
Compare the effect of Plasma Renin Concentration (PRC) and angiotensin II of aliskiren when given with and without light meal
Time Frame
28 Days
Title
Assess safety and tolerability of aliskiren when given with and without light meal
Time Frame
28 days
Title
Evaluate the effect on mean sitting systolic and diastolic blood pressure of aliskiren when given with or without a light meal
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female outpatients, 18 to 65 years of age with mild to moderate hypertension Patients who are eligible and able to participate in the study Exclusion criteria: Severe hypertension Secondary form of hypertension. Type 1 or type 2 diabetes mellitus Serum potassium out side laboratory reference range Any history of hypertensive encephalopathy or cerebrovascular accident Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigator Site
City
Coimbatore
Country
India
Facility Name
Novartis Investigative Site
City
Hyderabaad
Country
India
Facility Name
Novartis Investigator Site
City
Hyderabaad
Country
India
Facility Name
Novartis Investigator Site
City
Mangalore
Country
India
Facility Name
Novartis Investigative Site
City
New Delhi
Country
India

12. IPD Sharing Statement

Links:
URL
https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3763
Description
Results for CSPP100A2110 can be found on the Novartis Clinical Trial Results Website

Learn more about this trial

Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension

We'll reach out to this number within 24 hrs